Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTX Regimen for Advanced Biliary System Adenocarcinoma
NCT00868998Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Aug 2005
- Primary completion
- Sep 2010
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, docetaxel and capecitabine in cholangiocarcinoma (CCA), gallbladder cancer and Ampullary cancer (AC), sponsored by Columbia University. Primary endpoint: Response Rate at 10 weeks. Started Aug 2005; status: terminated.
02
Drugs
gemcitabinedocetaxelcapecitabine
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on NCT00868998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00868998.